Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Original ArticlesMaintenance Dialysis
You have accessRestricted Access

Characteristics of Colon-Derived Uremic Solutes

Robert D. Mair, Tammy L. Sirich, Natalie S. Plummer and Timothy W. Meyer
CJASN September 2018, 13 (9) 1398-1404; DOI: https://doi.org/10.2215/CJN.03150318
Robert D. Mair
Department of Medicine, Veterans Affairs Palo Alto Health Care System and Stanford University, Palo Alto, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tammy L. Sirich
Department of Medicine, Veterans Affairs Palo Alto Health Care System and Stanford University, Palo Alto, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natalie S. Plummer
Department of Medicine, Veterans Affairs Palo Alto Health Care System and Stanford University, Palo Alto, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy W. Meyer
Department of Medicine, Veterans Affairs Palo Alto Health Care System and Stanford University, Palo Alto, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Visual Overview

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Abstract

Background and objectives Colon microbial metabolism produces solutes that are normally excreted in the urine and accumulate in the plasma when the kidneys fail. This study sought to further identify and characterize human colon-derived uremic solutes.

Design, setting, participants, & measurements Colon-derived solutes normally excreted in the urine were identified by comparing urine from controls (n=17) and patients with total colectomies (n=12), using an established metabolomic platform. Colon-derived solutes that accumulate in kidney failure were then identified by comparing the plasma of the control patients with that of patients on dialysis (n=14).

Results Ninety-one urinary solutes were classified as colon-derived on the basis of the finding of a urine excretion rate at least four-fold higher in control patients than in patients with total colectomies. Forty-six were solutes with known chemical structure, 35 of which had not previously been identified as colon-derived. Sixty of the colon-derived solutes accumulated in the plasma of patients with ESKD to a degree greater than urea and were therefore classified as uremic. The estimated urinary clearance for 27 out of the 32 colon-derived solutes for which clearance could be calculated exceeded that of creatinine, consistent with tubular secretion. Sulfatase treatment revealed that 42 out of the 91 colon-derived solutes detected were likely conjugates.

Conclusions Metabolomic analysis identified numerous colon-derived solutes that are normally excreted in human urine. Clearance by tubular secretion limits plasma levels of many colon-derived solutes.

  • renal dialysis
  • creatinine
  • urea
  • Kidney Failure, Chronic
  • kidney
  • Renal Insufficiency
  • Metabolomics
  • Colon
  • Colectomy
  • Sulfatases

Introduction

Solutes normally excreted by the kidneys accumulate in CKD and cause uremic illness. Some of these uremic solutes are derived from colon microbes (1–6). Relatively few colon-derived uremic solutes have so far been chemically identified in humans. Attention has been concentrated on indoxyl sulfate, p-cresol sulfate, and tri-methylamine N-oxide, with substantial evidence for toxicity (7–9). These extensively studied solutes, however, are likely members of a much larger group.

This study sought to further characterize colon-derived solutes that accumulate in human kidney failure. Colon-derived solutes normally excreted by the kidneys were identified by comparing urine from control patients and patients who had undergone surgical colectomy. Comparison of plasma samples from the control patients and from patients undergoing maintenance hemodialysis then revealed the extent to which the colon-derived solutes accumulate in the plasma when the kidneys fail. Analysis of the plasma and urine of control patients allowed estimation of the efficiency with which the colon-derived solutes are normally cleared by the kidney. Use of an established metabolomic platform allowed chemical identification of an increased number of colon-derived solutes, along with detection of additional colon-derived solutes that have been repeatedly found in biologic samples but for which the chemical structure is not known. Treatment of urine with sulfatase tested whether the solutes without known chemical structure are conjugates.

Materials and Methods

Spot urine samples were collected from 17 patients with total colectomies. Colectomy patients were recruited if they had no active bowel disease, an eGFR >45 ml/min per 1.73 m2, a serum albumin above 3 g/dl, no weight loss over 5% in the past 6 months, and no use of antibiotics in the past month. In 12 patients, the small intestine drained through an ileostomy without any ileal pouch, and in the other five patients, an ileal pouch had been created to allow control of defecation. Simultaneous spot urine and plasma samples were collected from 17 age-matched control patients who had no known gastrointestinal or kidney disease and no use of antibiotics in the last month. Pretreatment plasma samples were also collected at the midweek treatment from 14 patients maintained on hemodialysis who had negligible residual urine output, no history of gastrointestinal disease, and no use of antibiotics in the past month. The study was approved by the Stanford Institutional Review Board and was conducted in accordance with the Declaration of Helsinki.

Sample Preparation and Analysis

Daily creatinine excretion was estimated using the formulas of Cockcroft and Gault (10) and urine samples were diluted with water to achieve the creatinine concentration expected if the urine flow had been 40 ml/min. This entailed dilution of individual samples over a range from 15 to 227-fold. The intent of this step was to obtain peak areas in urine closer to those in plasma ultrafiltrate and to limit errors in mass spectrometric estimations of urine concentration arising simply from variability of urine flow rate. A subset of six samples were also diluted to achieve the creatinine concentration expected if the urine flow had been 10 ml/min and 0.6 ml aliquots of these samples were treated with 100 U sulfatase (S0626; Sigma) in sodium acetate buffer pH6 or buffer alone for 6 hours at 37°C before analysis. Plasma ultrafiltrate was prepared using Nanosep 30 separators and concentrated four-fold by drying and resuspension in water.

Metabolomic analysis was performed by Metabolon, Inc., using a liquid chromatography–mass spectrometry platform to identify solutes and estimate their relative concentrations (11,12). Metabolites were identified by comparing masses, retention times, and fragmentation patterns with a chemical reference library including over 4000 chemically confirmed metabolites as well as unnamed metabolites without confirmed chemical structure that have been repeatedly detected by Metabolon in biologic samples (11–13). Absolute concentrations were also measured for urea using an enzymatic method, for creatinine using HPLC, and for selected organic anions using liquid chromatography–tandem mass spectrometry with isotopic dilution as previously described (14,15).

Calculations and Statistical Analyses

Relative urinary excretion rates were estimated from solute peak areas measured in samples diluted to provide a uniform estimated urine flow. Estimated excretion rates were normalized to a body surface area of 1.73 m2 using the formula of Mosteller (16). When no peak was detected for a given solute, a value equal to half of the smallest peak area detected in any sample of the same fluid type was imputed. Solutes were classified as colon-derived if their mean excretion rate was at least four-fold higher in individuals with intact colons than in those with total colectomies without ileal pouch and if the false discovery rate (q value) for the difference was <0.05. Solutes were classified as uremic if their mean peak area in plasma ultrafiltrate was at least 2.4-fold higher in patients on dialysis than the control patients, and the false discovery rate for difference was <0.05. The value of 2.4 was chosen because this was the ratio of urea peak areas in patients on dialysis relative to control patients.

The urinary clearance rate relative to creatinine was estimated by comparing peak areas in plasma ultrafiltrate and urine samples. The free, unbound fraction of solutes in the plasma was estimated by comparing peak areas in plasma ultrafiltrate and total plasma. Urinary clearance rates and free solute fractions were reported only when peak areas were measured in the urine, plasma and plasma ultrafiltrate of at least eight control patients. These calculations are on the basis of ratios of peak areas measured in different matrices and can provide only estimates of kidney clearance and protein binding. Conjugation of solutes without known chemical structure was assessed by comparing peak areas in urine samples treated with snail intestine sulfatase, which cleaves both sulfate and glucuronide conjugates, and with buffer control. Solutes without known chemical structure were classified as conjugates if they were detected in at least three of six urine samples and if sulfatase treatment reduced their peak area by an average of >80%. These criteria were chosen because they identified urinary solutes with known chemical structure as either sulfate or glucuronide conjugates, with a sensitivity of 70% and specificity of 97% (Supplemental Table 1).

P values were calculated using the Wilcoxon rank-sum test to compare mass spectrometry peak areas and the Pearson chi-squared test to compare the proportions of colon-derived and noncolon-derived solutes with specified characteristics. P values were obtained using Stata release 11 and false discovery rates (q-values) were calculated using software from http://qvalue.princeton.edu. This procedure identifies significant differences among a large number of comparisons at the expense of labeling a predetermined proportion of these comparisons (here, 0.05) as significant by chance (17).

Results

Characteristics of the study patients are summarized in Table 1 and further detailed in Supplemental Tables 2 and 3. The patients with colectomy appeared well nourished, with average body mass index of 26 kg/m2 and serum albumin of 3.7 g/dl. Their eGFR was similar to that of the control patients. Colectomy was performed for inflammatory bowel disease in nine out of 12 patients who had colectomies without ileal pouches and all five patients who had colectomies with ileal pouches.

View this table:
  • View inline
  • View popup
Table 1.

Patient characteristics

A total of 855 solutes were detected in the urine of control patients with intact colons. Of these, 464 were named solutes with known chemical structure and 391 were without known chemical structure. Ninety-one of these 855 urinary solutes were classified as colon-derived, including 46 with known chemical structure (Table 2) and 45 without known chemical structure (Supplemental Table 4). A careful literature search (Supplemental Table 5) revealed a known colonic origin for only the minority of the 46 colon-derived solutes with known chemical structure identified in this study. In contrast to the large number of solutes identified as colon-derived, none of the remaining 764 solutes had a four-fold higher urinary excretion rate in patients with colectomy compared with control patients, with a q value <0.05 for this difference.

View this table:
  • View inline
  • View popup
Table 2.

Colon-derived solutes excreted in human urine

A total of 880 solutes were detected in the pretreatment plasma samples of patients on maintenance hemodialysis. On the basis of comparison of peak areas in the plasma ultrafiltrate of patients on hemodialysis and control patients, 492 of these solutes were classified as uremic, including 278 with known chemical structure and 214 without known chemical structure (Supplemental Table 6). Solute levels in individual participants exhibited wide variability (Supplemental Table 7). The majority of the 91 colon-derived solutes excreted in the urine of control patients were classified as uremic, including 33 with known chemical structure (Table 2) and 27 without known chemical structure (Supplemental Table 4). Nineteen colon-derived solutes normally excreted in the urine could not be categorized because they were not detected in plasma ultrafiltrate and 12 others were not classified as uremic on the basis of their relative peak areas in plasma ultrafiltrate from patients on dialysis and control patients.

Simultaneous analysis of urine and plasma ultrafiltrate permitted estimation of the urinary clearance relative to creatinine for some of the colon-derived solutes (Supplemental Table 4, Table 2). Of note, the majority these solutes had a clearance more than two-fold higher than that of creatinine consistent with tubular secretion. Secretory clearance of many colon-derived solutes was associated with binding to plasma proteins (Table 3). Values for clearance and protein binding are on the basis of ratios of peak areas measured in different matrices and therefore can only be considered to be estimates. Measurements using quantitative assays with chemical standards largely confirmed the results obtained by metabolomic analysis (Table 4). In particular, these measurements suggested that metabolomic analysis had not overestimated the extent of microbial solute production or of solute accumulation in patients on dialysis. We have, however, previously observed discrepancies in the estimation of solute accumulation by metabolomic and quantitative analysis and suspect that metabolomic assessment of lower-abundance solutes may be particularly subject to error (18).

View this table:
  • View inline
  • View popup
Table 3.

Characteristics of colon-derived solutes

View this table:
  • View inline
  • View popup
Table 4.

Measurements by metabolomic and quantitative assays

Nearly half of the colon-derived solutes with known chemical structure were sulfate or glucuronide conjugates. Sulfatase treatment reduced the chromatographic peak areas by >80% in 23 out of the 45 colon-derived urinary solutes without known chemical structure, suggesting that these were sulfate or glucuronide conjugates (Supplemental Table 1, Table 3). Fifteen out of the 27 colon-derived uremic solutes without known chemical structure were among these presumed conjugates (Supplemental Table 4).

The estimated urine excretion rate for the colon-derived solutes in the 12 patients with total colectomy without ileal pouch averaged 11%±7% of that in control patients. In comparison, the estimated urinary excretion rate for the colon-derived solutes in the five patients with total colectomy with ileal pouch averaged 47%±37% of that in control patients (Supplemental Table 8). Statistical comparison was limited by the small patient number and by missing values, but the estimated excretion rate for each of the 87 colon-derived solutes detected in colectomy urine samples was numerically higher in the patients with pouches.

Discussion

Colon-derived uremic solutes have attracted particular interest because their production could prove easier to suppress than production of uremic solutes derived from mammalian metabolism (1–6). Despite this interest, relatively few colon-derived uremic solutes have so far been chemically identified in humans (Supplemental Table 5) (19–21). Examination of a small group of patients on dialysis with surgical colectomies suggested that the number of colon-derived uremic solutes in humans is large, but identified only six solutes (19). Many more colon-derived solutes have been identified in rats and mice in which suppression of microbial solute production is easier to accomplish. Studies in these species have identified at least 27 colon-derived solutes which are normally excreted in the urine and/or accumulate in the plasma when kidney function is reduced (Supplemental Table 5) (1,22–28).

This study greatly expands the list of colon-derived solutes known to accumulate in human kidney failure. We identified 33 such solutes, of which 22 had not been previously identified as colon-derived. It is important to emphasize that the number of solutes detected depends on the analytic method. We used the largest widely available metabolomic platform but it by no means detects the full array of solutes made by microbes (29). We also found that 27 solutes in the Metabolon database without known chemical identity are colon-derived solutes that accumulate in kidney failure. We suspect the total number of such solutes is in fact considerably larger than reported here, as no current analytic platform is capable of detecting the full spectrum of solutes in the human metabolome (11,18). Thirteen solutes previously identified as colon-derived uremic solutes were not identified as such in this study, as described in detail in Supplemental Table 9.

Most of the colon-derived solutes we identified had kidney clearances higher than that of creatinine. We presume these high clearances are achieved by secretory mechanisms that have been localized largely in the proximal tubule (30). Seven of the colon-derived uremic solutes are known substrates of proximal tubular organic anion transporters OAT1 and OAT3 (Supplemental Table 10) (12,31,32), including 2-oxindole-3-acetate and catechol sulfate, which have not previously been confirmed as colon-derived (Supplemental Table 5). For several of the colon-derived uremic solutes, binding to plasma proteins allowed estimated clearance rates expressed in terms of the free-solute concentration to exceed the estimated kidney plasma flow (Table 2). Such high clearance rates presumably serve to maintain the free solute levels of some toxic solutes very low. Our data suggest that a large portion of colon-derived solutes are protein bound and rapidly cleared by secretion (Table 3). The plasma levels of protein-bound secreted solutes tend to remain high in patients maintained on hemodialysis because the dialytic solute clearances are low relative to their clearances in the normal kidney (15). Indeed, the majority of the colon-derived urinary solutes are more than ten-fold elevated in the plasma ultrafiltrate of patients on hemodialysis compared with control patients (Table 3).

Almost half of the colon-derived uremic solutes with known chemical structure were sulfate or glucuronide conjugates and sulfatase treatment identified many of the unnamed colon-derived uremic solutes as likely conjugates. Conjugation in general is presumed to reduce toxicity and facilitate excretion (33). An additional 12 of the named colon-derived uremic solutes were amino-acid conjugates. Seven solutes were conjugates of amino acid and phenylacetic acid, which is produced by colon microbes from phenylalanine (21,34). One of these, phenylacetylglutamine, has been associated with cardiovascular disease and mortality in CKD (35). The finding of six additional amino-acid conjugates of phenylacetic acid suggests that molecules related to phenylacetylglutamine may accumulate in parallel. Phenylacetylmethionine and phenylacetylglutamate have been detected in human plasma and urine, respectively, but we did not find previous reports identifying the other conjugates (36,37). Of note, microbes can both oxidize and reduce amino acids. Thus, although phenylacetic acid is produced by oxidative metabolism of phenylalanine, cinnamoylglycine is produced by reductive metabolisms of the same amino acid. Similarly, p-cresol sulfate is produced by oxidative metabolism of tyrosine whereas 3-(3-Hydroxyphenyl) propanoic acid sulfate and 3-Hydroxyhippuric acid are produced by reductive metabolism of tyrosine.

Findings on some other solutes are worth noting. Indoleacetic acid has been shown to be prothrombotic in animals and to be independently associated with cardiovascular outcomes and mortality in patients with CKD (38,39). Fecal analysis has shown it is produced by colon microbes, but the extent to which its accumulation in host urine or plasma depends on microbial production has not been confirmed (12,40). Carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF) has been associated with gestational diabetes and impaired insulin production (41). Microbial origin of CMPF has been suspected but has not previously been confirmed in humans (27). CMPF has been classified as a uremic solute in past studies and was 2.6-fold elevated in patients on hemodialysis in this analysis, but did not meet statistical criteria as a uremic solute as it was only detected in half of the hemodialysis plasma ultrafiltrate samples (42).

We presume that solutes we have identified as colon-derived have their origin in microbial metabolisms rather than colon cell metabolism. Urinary excretion of solutes identified as colon-derived was consistently higher in patients with colectomy with ileal pouches than in those without pouches. This presumably represents solute production by microbes colonizing the pouches (43,44). These pouches have a volume on the order of 250–500 ml and the end ileal fluid resides in them at body temperature for some time, allowing microbial growth and metabolism (45,46). Microbial colonization of the end-ileum has also been demonstrated in colectomy patients without ileal pouches, which may account for urinary excretion of small quantities of colon-derived solutes in these patients (25,44). In addition, some solutes may be generated by both microbial and mammalian metabolism with the predominant process dependent on diet and species. Hippurate, which was not classified as colon-derived in this study, exemplifies this possibility (1,19,25,27).

Our study has limitations. The cutoffs for classification of solutes as colon-derived and uremic were arbitrary. Use of different cutoff values would yield different numbers of solutes in each class (Supplemental Table 11). The extent to which solutes accumulate in patients on dialysis depends on their dialytic clearance, which was not measured in this study. An important limitation of metabolomic analysis is that in obtaining data on large numbers of solutes we sacrifice accuracy in the determination of their individual concentrations. Calculations of urinary clearance and plasma protein binding on the basis of ratios of mass spectrometric peak areas measured in different matrices provide only estimates of the extent of tubular secretion and protein binding. Imputation of minimum peak area values when solute levels are below the limits of detection can also introduce errors in classification. In this study, nonparametric statistical analysis would not allow classification of a solute as uremic if it were detected in the plasma ultrafiltrate of fewer than eight out of the 17 control patients. Similar limitations apply to the classification of solutes as colon-derived. The patient number was small, and colon-derived solutes that are produced in a minority of people would not have been detected. Differences in urine solute excretion in patients with colectomy could be related to characteristics other than the absence of colon microbes. There could, for instance, be differences in diet and the prior history of inflammatory bowel disease in many patients with colectomy could contribute to group differences in metabolism. An even greater limitation of this study, however, is that no current metabolomic platform detects the whole range of solutes produced by mammalian or microbial metabolism. We thus suspect the number of colon-derived uremic solutes identified in humans will continue to increase.

In summary, metabolomic profiling of individuals with colectomies and normal kidney function identified 91 urinary colon-derived solutes, including over 30 named solutes not previously shown to be colon-derived. Many of these urinary colon-derived solutes were protein bound and efficiently eliminated by the kidney through tubular secretion. Most of them were shown to accumulate in kidney failure. Sulfatase treatment identified many colon-derived solutes without known chemical structure as conjugates. The toxicity of most uremic colon-derived solutes remains to be studied.

Disclosures

None.

Acknowledgments

We would like to thank the Stanford and Palo Alto Veterans Affairs colorectal surgery clinics for help recruiting patients.

This work was supported by National Institutes of Health awards (Ruth L. Kirschstein National Research Service Award F32 DK111166-01 to R.D.M. and R01 DK101674-01 to T.W.M.) and by an award from the Stanford Chemistry, Engineering & Medicine for Human Health program to T.W.M. T.L.S. was supported by a Veterans Affairs Career Development Award (CX-001036-01A1).

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • See related editorial, “Gut-Derived Metabolites and Chronic Kidney Disease: The Forest (F)or the Trees?,” on pages 1311–1313.

  • This article contains supplemental material online at http://cjasn.asnjournals.org/lookup/suppl/doi:10.2215/CJN.03150318/-/DCSupplemental.

  • Received March 9, 2018.
  • Accepted June 13, 2018.
  • Copyright © 2018 by the American Society of Nephrology

References

  1. ↵
    1. Kikuchi K,
    2. Itoh Y,
    3. Tateoka R,
    4. Ezawa A,
    5. Murakami K,
    6. Niwa T
    : Metabolomic search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878: 2997–3002, 2010pmid:20870466
    OpenUrlCrossRefPubMed
    1. Meyer TW,
    2. Hostetter TH
    : Uremic solutes from colon microbes. Kidney Int 81: 949–954, 2012pmid:22318422
    OpenUrlCrossRefPubMed
    1. Poesen R,
    2. Meijers B,
    3. Evenepoel P
    : The colon: An overlooked site for therapeutics in dialysis patients. Semin Dial 26: 323–332, 2013pmid:23458264
    OpenUrlCrossRefPubMed
    1. Ramezani A,
    2. Massy ZA,
    3. Meijers B,
    4. Evenepoel P,
    5. Vanholder R,
    6. Raj DS
    : Role of the gut microbiome in uremia: A potential therapeutic target. Am J Kidney Dis 67: 483–498, 2016pmid:26590448
    OpenUrlCrossRefPubMed
    1. Vanholder RC,
    2. Eloot S,
    3. Glorieux GL
    : Future avenues to decrease uremic toxin concentration. Am J Kidney Dis 67: 664–676, 2016pmid:26500179
  2. ↵
    1. Vaziri ND
    : Effect of synbiotic therapy on gut-derived uremic toxins and the intestinal microbiome in patients with CKD. Clin J Am Soc Nephrol 11: 199–201, 2016pmid:26772192
    OpenUrlFREE Full Text
  3. ↵
    1. Shashar M,
    2. Belghasem ME,
    3. Matsuura S,
    4. Walker J,
    5. Richards S,
    6. Alousi F,
    7. Rijal K,
    8. Kolachalama VB,
    9. Balcells M,
    10. Odagi M,
    11. Nagasawa K,
    12. Henderson JM,
    13. Gautam A,
    14. Rushmore R,
    15. Francis J,
    16. Kirchhofer D,
    17. Kolandaivelu K,
    18. Sherr DH,
    19. Edelman ER,
    20. Ravid K,
    21. Chitalia VC
    : Targeting STUB1-tissue factor axis normalizes hyperthrombotic uremic phenotype without increasing bleeding risk. Sci Transl Med 9: eaam8475, 2017pmid:29167396
    OpenUrlAbstract/FREE Full Text
    1. Tang WH,
    2. Wang Z,
    3. Levison BS,
    4. Koeth RA,
    5. Britt EB,
    6. Fu X,
    7. Wu Y,
    8. Hazen SL
    : Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 368: 1575–1584, 2013pmid:23614584
  4. ↵
    1. Vanholder R,
    2. Schepers E,
    3. Pletinck A,
    4. Nagler EV,
    5. Glorieux G
    : The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: A systematic review. J Am Soc Nephrol 25: 1897–1907, 2014pmid:24812165
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Cockcroft DW,
    2. Gault MH
    : Prediction of creatinine clearance from serum creatinine. Nephron 16: 31–41, 1976pmid:1244564
    OpenUrlCrossRefPubMed
  6. ↵
    1. Evans AM,
    2. Bridgewater BR,
    3. Liu Q,
    4. Mitchell MW,
    5. Robinson RJ,
    6. Dai H,
    7. Stewart SJ,
    8. DeHaven CD,
    9. Miller LAD
    : High resolution mass spectrometry improves data quantity and quality as compared to unit mass resolution mass spectrometry in high-throughput profiling metabolomics. Metabolomics 4: 132, 2014
  7. ↵
    1. Kennedy AD,
    2. Pappan KL,
    3. Donti TR,
    4. Evans AM,
    5. Wulff JE,
    6. Miller LAD,
    7. Reid Sutton V,
    8. Sun Q,
    9. Miller MJ,
    10. Elsea SH
    : Elucidation of the complex metabolic profile of cerebrospinal fluid using an untargeted biochemical profiling assay. Mol Genet Metab 121: 83–90, 2017pmid:28412083
  8. ↵
    1. Zhang Q,
    2. Ford LA,
    3. Evans AM,
    4. Toal DR
    : Structure elucidation of metabolite x17299 by interpretation of mass spectrometric data. Metabolomics 13: 92, 2017pmid:28706470
    OpenUrlCrossRefPubMed
  9. ↵
    1. Sirich TL,
    2. Aronov PA,
    3. Plummer NS,
    4. Hostetter TH,
    5. Meyer TW
    : Numerous protein-bound solutes are cleared by the kidney with high efficiency. Kidney Int 84: 585–590, 2013pmid:23636170
  10. ↵
    1. Sirich TL,
    2. Funk BA,
    3. Plummer NS,
    4. Hostetter TH,
    5. Meyer TW
    : Prominent accumulation in hemodialysis patients of solutes normally cleared by tubular secretion. J Am Soc Nephrol 25: 615–622, 2014pmid:24231664
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Mosteller RD
    : Simplified calculation of body-surface area. N Engl J Med 317: 1098, 1987pmid:3657876
    OpenUrlCrossRefPubMed
  12. ↵
    1. Storey JD
    : A direct approach to false discovery rates. J R Stat Soc Ser A Stat Soc 64: 479–498, 2002
  13. ↵
    1. Sirich TL,
    2. Aronov PA,
    3. Fullman J,
    4. Nguyen K,
    5. Plummer NS,
    6. Meyer TW
    : Untargeted mass spectrometry discloses plasma solute levels poorly controlled by hemodialysis. PLoS One 12: e0188315, 2017pmid:29145509
  14. ↵
    1. Aronov PA,
    2. Luo FJ,
    3. Plummer NS,
    4. Quan Z,
    5. Holmes S,
    6. Hostetter TH,
    7. Meyer TW
    : Colonic contribution to uremic solutes. J Am Soc Nephrol 22: 1769–1776, 2011pmid:21784895
    OpenUrlAbstract/FREE Full Text
    1. Nazzal L,
    2. Roberts J,
    3. Singh P,
    4. Jhawar S,
    5. Matalon A,
    6. Gao Z,
    7. Holzman R,
    8. Liebes L,
    9. Blaser MJ,
    10. Lowenstein J
    : Microbiome perturbation by oral vancomycin reduces plasma concentration of two gut-derived uremic solutes, indoxyl sulfate and p-cresyl sulfate, in end-stage renal disease. Nephrol Dial Transplant 32: 1809–1817, 2017pmid:28379433
    OpenUrlCrossRefPubMed
  15. ↵
    1. Tanaka H,
    2. Sirich TL,
    3. Plummer NS,
    4. Weaver DS,
    5. Meyer TW
    : An enlarged profile of uremic solutes. PLoS One 10: e0135657, 2015pmid:26317986
    OpenUrlCrossRefPubMed
  16. ↵
    1. Claus SP,
    2. Tsang TM,
    3. Wang Y,
    4. Cloarec O,
    5. Skordi E,
    6. Martin FP,
    7. Rezzi S,
    8. Ross A,
    9. Kochhar S,
    10. Holmes E,
    11. Nicholson JK
    : Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes. Mol Syst Biol 4: 219, 2008pmid:18854818
    OpenUrlAbstract/FREE Full Text
    1. Kikuchi M,
    2. Ueno M,
    3. Itoh Y,
    4. Suda W,
    5. Hattori M
    : Uremic toxin-producing gut microbiota in rats with chronic kidney disease. Nephron 135: 51–60, 2017pmid:27701177
    OpenUrlCrossRefPubMed
    1. Lee SH,
    2. An JH,
    3. Park HM,
    4. Jung BH
    : Investigation of endogenous metabolic changes in the urine of pseudo germ-free rats using a metabolomic approach. J Chromatogr B Analyt Technol Biomed Life Sci 887-888: 8–18, 2012pmid:22300547
    OpenUrlCrossRefPubMed
  17. ↵
    1. Mishima E,
    2. Fukuda S,
    3. Mukawa C,
    4. Yuri A,
    5. Kanemitsu Y,
    6. Matsumoto Y,
    7. Akiyama Y,
    8. Fukuda NN,
    9. Tsukamoto H,
    10. Asaji K,
    11. Shima H,
    12. Kikuchi K,
    13. Suzuki C,
    14. Suzuki T,
    15. Tomioka Y,
    16. Soga T,
    17. Ito S,
    18. Abe T
    : Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach. Kidney Int 92: 634–645, 2017pmid:28396122
    OpenUrlCrossRefPubMed
    1. Nicholls AW,
    2. Mortishire-Smith RJ,
    3. Nicholson JK
    : NMR spectroscopic-based metabonomic studies of urinary metabolite variation in acclimatizing germ-free rats. Chem Res Toxicol 16: 1395–1404, 2003pmid:14615964
    OpenUrlCrossRefPubMed
  18. ↵
    1. Wikoff WR,
    2. Anfora AT,
    3. Liu J,
    4. Schultz PG,
    5. Lesley SA,
    6. Peters EC,
    7. Siuzdak G
    : Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A 106: 3698–3703, 2009pmid:19234110
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Yap IK,
    2. Li JV,
    3. Saric J,
    4. Martin FP,
    5. Davies H,
    6. Wang Y,
    7. Wilson ID,
    8. Nicholson JK,
    9. Utzinger J,
    10. Marchesi JR,
    11. Holmes E
    : Metabonomic and microbiological analysis of the dynamic effect of vancomycin-induced gut microbiota modification in the mouse. J Proteome Res 7: 3718–3728, 2008pmid:18698804
    OpenUrlCrossRefPubMed
  20. ↵
    1. Donia MS,
    2. Fischbach MA
    : HUMAN MICROBIOTA. Small molecules from the human microbiota. Science 349: 1254766, 2015pmid:26206939
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Anzai N,
    2. Kanai Y,
    3. Endou H
    : Organic anion transporter family: Current knowledge. J Pharmacol Sci 100: 411–426, 2006pmid:16799257
    OpenUrlCrossRefPubMed
  22. ↵
    1. Hsueh CH,
    2. Yoshida K,
    3. Zhao P,
    4. Meyer TW,
    5. Zhang L,
    6. Huang SM,
    7. Giacomini KM
    : Identification and quantitative assessment of uremic solutes as inhibitors of renal organic anion transporters, OAT1 and OAT3. Mol Pharm 13: 3130–3140, 2016pmid:27467266
  23. ↵
    1. Deguchi T,
    2. Isozaki K,
    3. Yousuke K,
    4. Terasaki T,
    5. Otagiri M
    : Involvement of organic anion transporters in the efflux of uremic toxins across the blood-brain barrier. J Neurochem 96: 1051–1059, 2006pmid:16445853
    OpenUrlCrossRefPubMed
  24. ↵
    1. Yi L,
    2. Dratter J,
    3. Wang C,
    4. Tunge JA,
    5. Desaire H
    : Identification of sulfation sites of metabolites and prediction of the compounds’ biological effects. Anal Bioanal Chem 386: 666–674, 2006pmid:16724218
    OpenUrlCrossRefPubMed
  25. ↵
    1. Seakins JW
    : The determination of urinary phenylacetylglutamine as phenylacetic acid. Studies on its origin in normal subjects and children with cystic fibrosis. Clin Chim Acta 35: 121–131, 1971pmid:5126986
    OpenUrlCrossRefPubMed
  26. ↵
    1. Poesen R,
    2. Claes K,
    3. Evenepoel P,
    4. de Loor H,
    5. Augustijns P,
    6. Kuypers D,
    7. Meijers B
    : Microbiota-derived phenylacetylglutamine associates with overall mortality and cardiovascular disease in patients with CKD. J Am Soc Nephrol 27: 3479–3487, 2016pmid:27230658
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Liebich HM,
    2. Först C
    : Basic profiles of organic acids in urine. J Chromatogr A 525: 1–14, 1990pmid:2338430
    OpenUrlCrossRefPubMed
  28. ↵
    1. Stanstrup J,
    2. Schou SS,
    3. Holmer-Jensen J,
    4. Hermansen K,
    5. Dragsted LO
    : Whey protein delays gastric emptying and suppresses plasma fatty acids and their metabolites compared to casein, gluten, and fish protein. J Proteome Res 13: 2396–2408, 2014pmid:24708224
    OpenUrlCrossRefPubMed
  29. ↵
    1. Chitalia VC,
    2. Shivanna S,
    3. Martorell J,
    4. Balcells M,
    5. Bosch I,
    6. Kolandaivelu K,
    7. Edelman ER
    : Uremic serum and solutes increase post-vascular interventional thrombotic risk through altered stability of smooth muscle cell tissue factor. Circulation 127: 365–376, 2013pmid:23269489
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Dou L,
    2. Sallée M,
    3. Cerini C,
    4. Poitevin S,
    5. Gondouin B,
    6. Jourde-Chiche N,
    7. Fallague K,
    8. Brunet P,
    9. Calaf R,
    10. Dussol B,
    11. Mallet B,
    12. Dignat-George F,
    13. Burtey S
    : The cardiovascular effect of the uremic solute indole-3 acetic acid. J Am Soc Nephrol 26: 876–887, 2015pmid:25145928
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Lamas B,
    2. Richard ML,
    3. Leducq V,
    4. Pham HP,
    5. Michel ML,
    6. Da Costa G,
    7. Bridonneau C,
    8. Jegou S,
    9. Hoffmann TW,
    10. Natividad JM,
    11. Brot L,
    12. Taleb S,
    13. Couturier-Maillard A,
    14. Nion-Larmurier I,
    15. Merabtene F,
    16. Seksik P,
    17. Bourrier A,
    18. Cosnes J,
    19. Ryffel B,
    20. Beaugerie L,
    21. Launay JM,
    22. Langella P,
    23. Xavier RJ,
    24. Sokol H
    : CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med 22: 598–605, 2016pmid:27158904
    OpenUrlCrossRefPubMed
  32. ↵
    1. Prentice KJ,
    2. Luu L,
    3. Allister EM,
    4. Liu Y,
    5. Jun LS,
    6. Sloop KW,
    7. Hardy AB,
    8. Wei L,
    9. Jia W,
    10. Fantus IG,
    11. Sweet DH,
    12. Sweeney G,
    13. Retnakaran R,
    14. Dai FF,
    15. Wheeler MB
    : The furan fatty acid metabolite CMPF is elevated in diabetes and induces β cell dysfunction. Cell Metab 19: 653–666, 2014pmid:24703697
    OpenUrlCrossRefPubMed
  33. ↵
    1. Vanholder R,
    2. De Smet R,
    3. Glorieux G,
    4. Argilés A,
    5. Baurmeister U,
    6. Brunet P,
    7. Clark W,
    8. Cohen G,
    9. De Deyn PP,
    10. Deppisch R,
    11. Descamps-Latscha B,
    12. Henle T,
    13. Jörres A,
    14. Lemke HD,
    15. Massy ZA,
    16. Passlick-Deetjen J,
    17. Rodriguez M,
    18. Stegmayr B,
    19. Stenvinkel P,
    20. Tetta C,
    21. Wanner C,
    22. Zidek W; European Uremic Toxin Work Group (EUTox)
    : Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int 63: 1934–1943, 2003pmid:12675874
    OpenUrlCrossRefPubMed
  34. ↵
    1. Falk A,
    2. Olsson C,
    3. Ahrné S,
    4. Molin G,
    5. Adawi D,
    6. Jeppsson B
    : Ileal pelvic pouch microbiota from two former ulcerative colitis patients, analysed by DNA-based methods, were unstable over time and showed the presence of Clostridium perfringens. Scand J Gastroenterol 42: 973–985, 2007pmid:17613928
    OpenUrlCrossRefPubMed
  35. ↵
    1. Hinata M,
    2. Kohyama A,
    3. Ogawa H,
    4. Haneda S,
    5. Watanabe K,
    6. Suzuki H,
    7. Shibata C,
    8. Funayama Y,
    9. Takahashi K,
    10. Sasaki I,
    11. Fukushima K
    : A shift from colon- to ileum-predominant bacteria in ileal-pouch feces following total proctocolectomy. Dig Dis Sci 57: 2965–2974, 2012pmid:22539039
    OpenUrlCrossRefPubMed
  36. ↵
    1. Hallgren T,
    2. Fasth S,
    3. Nordgren S,
    4. Oresland T,
    5. Hallsberg L,
    6. Hultén L
    : Manovolumetric characteristics and functional results in three different pelvic pouch designs. Int J Colorectal Dis 4: 156–160, 1989pmid:2768996
    OpenUrlCrossRefPubMed
  37. ↵
    1. Kjaer MD,
    2. Simonsen JA,
    3. Hvidsten S,
    4. Kjeldsen J,
    5. Gerke O,
    6. Qvist N
    : Scintigraphic small intestinal transit time and defaecography in patients with J-Pouch. Diagnostics (Basel) 5: 399–412, 2015pmid:26854162
    1. Wishart DS,
    2. Feunang YD,
    3. Marcu A,
    4. Guo AC,
    5. Liang K,
    6. Vázquez-Fresno R,
    7. Sajed T,
    8. Johnson D,
    9. Li C,
    10. Karu N,
    11. Sayeeda Z,
    12. Lo E,
    13. Assempour N,
    14. Berjanskii M,
    15. Singhal S,
    16. Arndt D,
    17. Liang Y,
    18. Badran H,
    19. Grant J,
    20. Serra-Cayuela A,
    21. Liu Y,
    22. Mandal R,
    23. Neveu V,
    24. Pon A,
    25. Knox C,
    26. Wilson M,
    27. Manach C,
    28. Scalbert A
    : HMDB 4.0: The human metabolome database for 2018. Nucleic Acids Res 46[D1]: D608–D617, 2018pmid:29140435
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 13 (9)
Clinical Journal of the American Society of Nephrology
Vol. 13, Issue 9
September 07, 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Characteristics of Colon-Derived Uremic Solutes
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Characteristics of Colon-Derived Uremic Solutes
Robert D. Mair, Tammy L. Sirich, Natalie S. Plummer, Timothy W. Meyer
CJASN Sep 2018, 13 (9) 1398-1404; DOI: 10.2215/CJN.03150318

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Characteristics of Colon-Derived Uremic Solutes
Robert D. Mair, Tammy L. Sirich, Natalie S. Plummer, Timothy W. Meyer
CJASN Sep 2018, 13 (9) 1398-1404; DOI: 10.2215/CJN.03150318
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Visual Overview
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

Original Articles

  • Short-Duration Prednisolone in Children with Nephrotic Syndrome Relapse
  • Associations between Deprivation, Geographic Location, and Access to Pediatric Kidney Care in the United Kingdom
  • Variability in Culture-Negative Peritonitis Rates in Pediatric Peritoneal Dialysis Programs in the United States
Show more Original Articles

Maintenance Dialysis

  • The Mobile Health Readiness of People Receiving In-Center Hemodialysis and Home Dialysis
  • Effect of Phosphate-Specific Diet Therapy on Phosphate Levels in Adults Undergoing Maintenance Hemodialysis
  • Zolpidem Versus Trazodone Initiation and the Risk of Fall-Related Fractures among Individuals Receiving Maintenance Hemodialysis
Show more Maintenance Dialysis

Cited By...

  • Why Is the GFR So High?: Implications for the Treatment of Kidney Failure
  • Impaired Tubular Secretion of Organic Solutes in Acute Kidney Injury
  • Assessing Clinical Relevance of Uremic Toxins
  • Google Scholar

Similar Articles

Related Articles

  • Gut-Derived Metabolites and Chronic Kidney Disease
  • PubMed
  • Google Scholar

Keywords

  • renal dialysis
  • creatinine
  • urea
  • Kidney Failure, Chronic
  • kidney
  • renal insufficiency
  • Metabolomics
  • Colon
  • Colectomy
  • Sulfatases

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire